Gion M, Mione R, Pappagallo G L, Gatti C, Nascimben O, Brandes A, Vinante O, Bruscagnin G
Centro Regionale Indicatori Biochimici di Tumore, Ospedale Civile, ULSS 16 Venezia, Italy.
Eur J Cancer. 1992;29A(1):66-9. doi: 10.1016/0959-8049(93)90578-4.
Since 1982 we have been evaluating oestrogen and progesterone receptors (PgR), cathepsin D and the cytosolic levels of the tumour marker, tissue polypeptide antigen (TPA), in 257 patients radically resected for breast cancer (follow-up 24-81 months). TPA was measured by an immunoradiometric assay previously validated for cytosol. No significant associations were found between cytosolic TPA and age, tumour size, lymph-node status, receptor status and cathepsin D. TPA+ cases showed a significantly longer disease-free survival (DFS) and overall survival (OS) than TPA-patients (log-rank P < 0.0001). The prognostic value of cytosolic TPA was also demonstrated after stratification by nodal status, PgR and cathepsin D. The prognostic value of TPA was independent of the other prognostic indicators, being the most powerful among the evaluated indices (Cox multivariate analysis: chi 2 15.5 for DFS, 11.4 for OS). We conclude that cytosolic TPA is a powerful additional prognostic factor in primary breast cancer. Its prognostic role should therefore be extensively evaluated.
自1982年以来，我们一直在对257例接受乳腺癌根治术的患者（随访24 - 81个月）的雌激素和孕激素受体（PgR）、组织蛋白酶D以及肿瘤标志物组织多肽抗原（TPA）的胞浆水平进行评估。TPA采用先前已针对胞浆进行验证的免疫放射分析方法进行测定。未发现胞浆TPA与年龄、肿瘤大小、淋巴结状态、受体状态及组织蛋白酶D之间存在显著关联。TPA阳性病例的无病生存期（DFS）和总生存期（OS）显著长于TPA阴性患者（对数秩检验P < 0.0001）。在按淋巴结状态、PgR和组织蛋白酶D分层后，也证实了胞浆TPA的预后价值。TPA的预后价值独立于其他预后指标，是所评估指标中最具预测力的指标（Cox多因素分析：DFS的χ²为15.5，OS的χ²为11.4）。我们得出结论，胞浆TPA是原发性乳腺癌中一个强大的额外预后因素。因此，其预后作用应得到广泛评估。
